Wednesday September 23, 2020

Are pharma risks worth it for investors?

Merger and acquisition activity is hotting up in the pharmaceutical sector, but investors need to keep the risk factor in mind , writes Emma Kennedy.

23rd February, 2014

Deals being struck in the pharma sector could turn out to be a welcome boost for investors, but weighing up the risk is key.

A significant level of merger and acquisition (M&A) activity in the pharma sector is likely to pique investor interest, and leave them considering the role that pharma stocks should play in their investment portfolio.

Last week saw Dublin-based Actavis Plc, a major generic drug maker, agree to buy Forest...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

This product does not auto-renew

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

The best writing and and the biggest stories of 2019 from the Business Post

Richie Oakley | 8 months ago

Denis O’Brien is back in court, residents continue to fight the Council on halting site and a row surfaces in government over rent control proposals

Leanna Byrne | 4 years ago